English
Polski
Español
українська
русский
Bisphosphonates in patients with moderate renal impairment
Can bisphosphonates be used in patients with moderate renal impairment? What are the potential adverse effects of these drugs? Is denosumab a better choice in such patients?
2019-01-30
Can bisphosphonates be used in patients with moderate renal impairment? What are the potential adverse effects of these drugs? Is denosumab a better choice in such patients?
What is new in the 2014 International Criteria for Behçet Disease?
What is the effectiveness of pharmacological treatment of osteoporosis in elderly patients? Do bisphosphonates reduce the risk of fractures if started late in life, eg, in patients aged >80 years?
Is plasmapheresis an effective treatment in rheumatologic emergencies?
Secondary amyloidosis is a potentially fatal complication of chronic inflammatory diseases. When should it be suspected?
Is frailty associated with a risk of fractures? Is quantitative assessment of frailty possible?
When should we use plasmapheresis in rheumatologic emergencies?
How can we predict osteoporotic fractures in an elderly patient? What are the best tools to diagnose osteoporosis that help in decision-making?
Can biologic treatment be restarted in a patient who developed tuberculosis (TB) while on anti–tumor necrosis factor (TNF) treatment? Can we use anti-TNF agents again in such patients?
McMaster Textbook of Internal Medicine acknowledges the important contribution of Cochrane Canada and its authors in development of the textbook.